Search clinical trials for: Simeprevir

Total 98 results

Janssen Research & Development, LLC

Completed

An Efficacy, Safety and Pharmacokinetics Study of Simeprevir, Daclatasvir and Sofosbuvir in Participants With Chronic Hepatitis C Virus Genotype 1 or 4 Infection and Decompensated Liver Disease

Hepatitis C, Chronic

United States
Peter J. Ruane, M.D.
Janssen Scientific Affairs, LLC

Completed

Simeprevir in Combination With Sofosbuvir in Treatment-Naïve or -Experienced Adults With Chronic Genotype 4 Hepatitis C Virus Infection

Chronic Hepatitis C

United States
Janssen R&D Ireland
Gilead Sciences

Completed

A Study of TMC435 in Combination With PSI-7977 (GS7977) in Chronic Hepatitis C Genotype 1-Infected Prior Null Responders To Peginterferon/Ribavirin Therapy or HCV Treatment-Naive Patients (COSMOS)

Hepatitis C

United States, Puerto Rico
SC Liver Research Consortium, LLC
Janssen, LP

Completed

SMV + SOF With/Without RBV for IFN-II Patients With CHC

Hepatitis C

United States
Merck Sharp & Dohme LLC
Janssen Research & Development, LLC

Completed

Drug-Drug Interaction Between IDX719, Simeprevir, TMC647055 and Ritonavir When Administered in Combination in Healthy Participants (MK-1894-007)

Hepatitis C, Chronic
Cairo University

Unknown

Evaluation of Clinical Performance of 3D Printed Polyether Ether Ketone (PEEK) Inlays

Occlusal Caries
Tibotec Pharmaceuticals, Ireland

Completed

A Study of TMC435350 Administered With or Without Standard of Care Therapy in Participants With Genotype 1 Hepatitis C Virus Infection

Hepatitis C, Chronic

France, United Kingdom, Belgium, Germany, Poland, Netherlands
Janssen R&D Ireland

Completed

An Efficacy, Pharmacokinetics, Safety and Tolerability Study of TMC435 as Part of a Treatment Regimen for Hepatitis C-Infected Patients

Hepatitis C, Chronic

China, Korea, Republic of
Tibotec Pharmaceuticals, Ireland

Completed

TMC435-TiDP16-C116 - Relative Bioavailability and Food Effect Study

Hepatitis C
Janssen Research & Development, LLC

Completed

To Evaluate the Effects of Odalasvir and AL-335 With Simeprevir on the Single-Dose Pharmacokinetics of Ethinylestradiol and Drospirenone in Healthy Female Participants

Healthy

United States
Medical University of Graz
CBmed Ges.m.b.H.

Recruiting

Effect of L-ornithine-L-aspertate (LOLA) on the Gut Microbiome (LOLAbiome)

Cirrhosis

Austria
Hoffmann-La Roche

Terminated

An Observational Study Examining the Use of Triple Combination Therapy With Boceprevir, Peginterferon Alfa-2a and Ribavirin in the Re-Treatment of Chronic Hepatitis C Patients

Hepatitis C, Chronic

Hungary
Janssen Research & Development, LLC

Completed

A Pharmacokinetic Interaction Study Between TMC435, Atorvastatin and Simvastatin in Healthy Participants

Healthy Participants

United States
Tibotec Pharmaceuticals, Ireland

Completed

A Study of TMC435 in Combination With Pegylated Interferon Alp\Fa-2a and Ribavirin in Patients Infected With Genotype 1 Hepatitis C Virus Who Never Received Treatment (PILLAR)

Hepatitis C

United States, Australia, France, Belgium, Germany, Spain, Denmark, Canada, New Zealand, Russian Federation, Austria, Poland, Norway
Janssen Pharmaceutical K.K.

Completed

A Study of TMC435 in Genotype 1, Hepatitis C-infected Patients Who Relapsed After Previous Interferon (IFN)-Based Therapy

Hepatitis C, Chronic

Japan
Janssen Pharmaceutical K.K.

Completed

A Study of TMC435 in Participants With Genotype 1 Hepatitis C Virus (HCV) Infection

Hepatitis C, Chronic

Japan
Tanta University

Completed

Safety and Efficacy of Sofosbuvir-Based Regimens in the Treatment of Egyptian Patients With Hepatitis C Infection

Hepatitis C

Egypt
Janssen R&D Ireland

Completed

An Efficacy, Safety, and Tolerability Study of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected Patients (QUEST-1)

Hepatitis C

United States, Australia, Ukraine, United Kingdom, Germany, Spain, Mexico, Canada, New Zealand, Russian Federation, Puerto Rico, Romania
Janssen Pharmaceutical K.K.

Completed

A Phase III Study of TMC435 in Treatment-naive, Genotype 1, Hepatitis C-infected Patients

Hepatitis C, Chronic

Japan
Janssen Pharmaceutical K.K.

Completed

A Phase III Study of TMC435 in Genotype 1, Hepatitis C-infected Participants Who Failed to Respond to Previous IFN-based Therapy

Hepatitis C, Chronic

Japan
Tibotec Pharmaceuticals, Ireland

Completed

TMC435-TiDP16-C125 - Study in Healthy Volunteers to Evaluate the Potential of TMC435 to Increase the Sensitivity of the Skin Towards Exposure to Sun Light

Hepatitis C Virus
Tibotec Pharmaceuticals, Ireland

Completed

A Safety and Effectiveness Study of TMC435 in Chronic, Genotype 1, Hepatitis C Patients Who Failed to Previous Standard Treatment (ASPIRE)

Hepatitis C

United States, Australia, France, United Kingdom, Belgium, Germany, Israel, Portugal, Canada, New Zealand, Russian Federation, Austria, Poland, Norway
Janssen R&D Ireland

Completed

An Efficacy, Safety and Tolerability Study of TMC435 in Genotype 1 Hepatitis C-infected Patients Who Relapsed After Previous Therapy (PROMISE)

Hepatitis C

United States, Australia, France, Poland, United Kingdom, Belgium, Germany, Spain, Canada, New Zealand, Russian Federation, Puerto Rico, Austria
Tibotec Pharmaceuticals, Ireland

Completed

TMC435-TiDP16-C114 - A Study in Healthy Volunteers Investigating the Pharmacokinetic Interaction Between TMC435 and the Antiretroviral Agents TMC278 and Tenofovir

Hepatitis C Virus
Tibotec Pharmaceuticals, Ireland

Completed

A Study in Healthy Participants Investigating the Effect of TMC435 on the Pharmacokinetics of Immunosuppressants Cyclosporine and Tacrolimus

Hepatitis C Virus

Belgium
Janssen R&D Ireland

Completed

A Study of Pharmacokinetics, Efficacy, Safety, Tolerability, of the Combination of Simeprevir (TMC435), Daclatasvir (BMS-790052), and Ribavirin (RBV) in Patients With Recurrent Chronic Hepatitis C Genotype 1b Infection After Orthotopic Liver Transplantation

Hepatitis C, Chronic

Spain, Germany, Poland
Parc de Salut Mar

Completed

Impact of Antiviral Therapy on Gastroesophageal Varices.

Cirrhosis | Chronic Hepatitis C
Assiut University
Sohag University; South Valley University

Completed

Comparative Study of Two Regiemns in Management of Sofosbuvir/Daclatasvir Failure

HCV Coinfection

Egypt
Tibotec Pharmaceuticals, Ireland

Completed

A Study to Investigate the Potential Pharmacokinetic Interaction Between TMC435 and Methadone

Hepatitis C

Canada
Janssen R&D Ireland

Completed

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of TMC647055 in Combination With Ritonavir (Part 1) and the Co-administration of TMC435, TMC647055 and Ritonavir (Part 2) in Healthy Japanese Participants

Healthy

United Kingdom
Tibotec Pharmaceuticals, Ireland

Completed

A Study of Drug-drug Interaction Between Ritonavir and TMC435350 in Healthy Volunteers

Healthy

Belgium
Janssen R&D Ireland

Completed

A Study to Assess the Safety, Tolerability and Efficacy of TMC435 Along With Pegylated Interferon Alpha-2a (Pegasys) and Ribavirin (Copegus) Triple Therapy in Chronic Hepatitis C Genotype-1 Infected Patients Co-infected With Human Immunodeficiency Virus-Type 1

Hepatitis C Virus Genotype-1

United States, France, United Kingdom, Germany, Spain, Portugal, Canada, Puerto Rico
Janssen-Cilag International NV

Completed

A Study of TMC435 Plus Pegylated Interferon Alfa-2a and Ribavirin in Participants With Chronic HCV Infection

Hepatitis C, Chronic | Infection

United Kingdom, Germany, Spain, Belgium, Saudi Arabia, Austria, France
Tibotec Pharmaceuticals, Ireland

Completed

TMC435-TiDP16-C108 - A Study in Healthy Volunteers Investigating the Pharmacokinetic Interaction Between TMC435 and Digoxin and Between TMC435 and Rosuvastatin

Hepatitis C Virus
National Hepatology & Tropical Medicine Research...
Cairo University

Unknown

Impact of Interferon Free Regimens in Patients With Chronic HCV and Successfully Treated HCC (FRI-STC)

Hepatocellular Carcinoma | Hepatitis C, Chronic

Egypt
Center For Hepatitis C, Atlanta, GA

Completed

The SIM-SOF Trial for Hepatitis C

Chronic Hepatitis C

United States
Janssen R&D Ireland

Completed

A Study to Assess Bioavailability & Food Effect of Different Liquid and Capsule Formulations of TMC435.

Healthy Volunteers

United Kingdom
Janssen R&D Ireland

Completed

An Efficacy, Safety, and Tolerability Study of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected Participants (QUEST-2)

Hepatitis C

United States, France, Poland, Belgium, Germany, Spain, Portugal, Bulgaria, Turkey, Argentina, Brazil, Austria, Netherlands, Slovakia, Puerto Rico
Tibotec Pharmaceuticals, Ireland

Completed

TMC435-TiDP16-C115 - A Study in Healthy Volunteers Investigating the Pharmacokinetic Interaction Between TMC435 and Erythromycin and Between TMC435 and Darunavir/Ritonavir (DRV/r)

Hepatitis C Virus

Belgium
Tibotec Pharmaceuticals, Ireland

Completed

TMC435-TiDP16-C117: The Effect of TMC435 on the Results of Electrocardiograms (Electric Recording of the Heart) in Healthy Volunteers

Hepatitis C
Janssen R&D Ireland

Completed

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK2336805 Alone and With the Co-administration of TMC435 in Healthy Japanese Participants.

Healthy

United States
Tibotec Pharmaceuticals, Ireland

Completed

TMC435350-TiDP16-C105: Phase I, 3-way Crossover, Drug-drug Interaction Between TMC435350 and Rifampin After Multiple Dosing.

Hepatitis C | Tuberculosis | Pharmacokinetics | HCV | Rifampin
Merck Sharp & Dohme LLC
Janssen Research & Development, LLC

Completed

Samatasvir (IDX719) in Combinations With Simeprevir and/or TMC647055/Ritonavir With or Without Ribavirin for 12 Weeks in Participants With Chronic Hepatitis C Infection (MK-1894-005)

Chronic Hepatitis C Virus
Tibotec Pharmaceuticals, Ireland

Completed

TMC435-TiDP16-C112 - Interaction Trial With Antidepressants

Hepatitis C Virus
Valme University Hospital
Hospital General Universitario Elche; Hospital del SAS de Jerez; Clinica Universidad... and other collaborators

Completed

Efficacy and Safety of Therapy Against HCV Based on Direct-acting Antivirals in Real-life Conditions (FPSMON201401)

Chronic Hepatitis C Infection

Spain
Tibotec Pharmaceuticals, Ireland

Completed

TMC435-TiDP16-C123 - A Study in Healthy Volunteers Investigating the Pharmacokinetic Interaction Between TMC435 and the Antiretroviral Agents Efavirenz and Raltegravir

Hepatitis C Virus

Germany
Janssen R&D Ireland

Completed

A Study to Evaluate the Safety, Tolerability, and Effectiveness of a 12-Week Combination Therapy of TMC647055 and TMC435 With and Without GSK23336805 With a Pharmacokinetic Enhancer With and Without Ribavirin in Patients Infected With Chronic Genotype 1 Hepatitis C Virus

Chronic Hepatitis C

Belgium, Germany
Humanity and Health Research Centre
Beijing 302 Hospital; Nanfang Hospital of Southern Medical University

Recruiting

Switching Regimen in Treating Cirrhotic HCV GT1b Subjects (SWITCH-1)

Chronic Hepatitis C Infection

China

3

Subscribe